IP Library Granted Patent US 12,168,676
Granted Patent B2
US 12,168,676 · App. 17/420,813 · Granted Dec 17, 2024

Microbially derived peptides and proteins for immunotherapy

Inventors: Yuliya Katlinskaya (Brisbane, CA); Helena Kiefel (Brisbane, CA); Kareem L. Graham (Brisbane, CA); Todd Z. DeSantis (Brisbane, CA); Sunit Jain (Brisbane, CA); Andrew W. Han (Brisbane, CA); Karim Dabbagh (Brisbane, CA)
Assignee: Genevive, Inc.
C07K14/195A61P35/00A61P37/04A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,168,676
App. No.
17/420,813
Granted
Dec 17, 2024
Kind
B2
Abstract

The disclosure provides therapeutic peptides and pharmaceutical compositions comprising the peptides, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system to mitigate disease.

Claims (13)

1. A method for treating a disease in a subject in need thereof, comprising:

administering to the subject a pharmaceutical composition, comprising:

i. a therapeutic peptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1; and

ii. a pharmaceutically acceptable carrier.

2. The method according to claim 1 , wherein the peptide comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:1.

3. The method according to claim 1 , wherein the peptide comprises the amino acid sequence of SEQ ID NO:1.

4. The method according to claim 1 , wherein the peptide modulates the production of at least one cytokine in the subject.

5. The method according to claim 1 , wherein the peptide modulates the production of at least one cytokine in the subject wherein the cytokine is selected from the group consisting of TNF-α, IL-17, IL-1β, IL-2, IFN-γ, IL-6, IL-12, IL-25, IL-33, IL-8, MCP-1, MIP-3α, CXCL1, IL-23, IL-4, IL-10, IL-13, IFN-α, and TGF-β.

6. The method according to claim 1 , wherein the peptide increases Th1 activation, increases dendritic cell maturation, increases CD70 expression, or increases the clonal expansion of T eff in the subject.

7. The method according to claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

8. The method according to any claim 1 , wherein the disease is a neoplasm.

9. The method according to claim 1 , wherein the disease is cancer.

10. The method according to claim 1 , wherein the disease is at least one selected from the group consisting of: basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, cervical cancer, choriocarcinoma, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, kidney cancer, larynx cancer, leukemia, liver cancer, small-cell lung cancer, non-small-cell lung cancer, Hodgkin's lymphoma, non-Hodgkins lymphoma, melanoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, renal cancer, cancer of the respiratory system, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, or cancer of the urinary system.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2024
From: SECOND GENOME, INC.
To: GENEVIVE, INC.
Reel/Frame 065994/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2021
From: KATLINSKAYA, YULIYA; KIEFEL, HELENA; GRAHAM, KAREEM L.; DESANTIS, TODD ZACHARY; JAIN, SUNIT; HAN, ANDREW W.; DABBAGH, KARIM
To: SECOND GENOME, INC.
Reel/Frame 056877/0181 →
Continuity (2)
Provisional Application 62788950 · Jan 6, 2019
Related Publication 20220089653A1 · Mar 24, 2022